Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
Saved in:
| Published in: | JAC-Antimicrobial Resistance |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
- Selected β-lactam resistance in selected species of gram-negative bacteria
- Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis
- In vitro activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019
- Changes in physical performance with aging in master athletes and in the general population: an update